Clinical Scorecard: Are AI Models Cheating in Biomarker Predictions?

At a Glance

Key Highlights

• AI models often confound biomarker predictions with unrelated clinical factors.
• Performance varies significantly based on related biomarkers and tumor characteristics.
• Simple models using pathologist-assigned grades can rival complex AI systems.
• Current AI approaches may not be robust enough to replace molecular assays.
• Bias-aware validation strategies are essential for clinical deployment.

Guideline-Based Recommendations

Diagnosis

• Use stratified analyses to evaluate AI model performance in relevant subgroups.

Management

• Confirmatory molecular testing remains essential for treatment decisions.

Monitoring & Follow-up

• Implement bias-aware validation strategies before routine use of AI systems.

Risks

• Overreliance on aggregate accuracy metrics may misrepresent clinical utility.

Patient & Prescribing Data

Patients with various cancer types undergoing biomarker testing.

AI tools can assist in triage but should not replace molecular assays.

Clinical Best Practices

• Ensure AI models demonstrate information gain beyond simple pathologist-assigned grades.
• Adopt stricter evaluation protocols for AI algorithms.

References

• Nature Biomedical Engineering